Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer – guidance (TA643)

Entrectinib is recommended as an option for treating ROS1-positive advanced non-small-cell lung cancer in adults who have not had ROS1 inhibitors.

Source:

National Institute for Health and Care Excellence